Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Immix Biopharma shares gained 44.5% in pre-market trading after disclosing positive clinical results for NXC-201 at The American Society of Gene and Cell Therapy. Other pre-market gainers include SeqLL, CNS Pharmaceuticals, Hepion Pharmaceuticals, and Netcapital. Losers in pre-market trading include Volcon, Daxor Corporation, SunCar Technology Group, Mallinckrodt, and IZEA Worldwide.
May 22, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immix Biopharma shares gained 44.5% in pre-market trading after disclosing positive clinical results for NXC-201 at The American Society of Gene and Cell Therapy.
Immix Biopharma's positive clinical results for NXC-201 are a significant development for the company, which is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100